Pulling SEC filings + quote and writing the call…

Penumbra Inc
Next earnings Jul 27, 2026 (after close) · consensus $1.20 EPS, $393M rev
Last earnings +0.1% on 2026-05-06
High-growth medical-device maker hitting a profitability inflection with 67% gross margins, but a 70x P/E prices the good news in.
Penumbra is a fast-growing maker of surgical and medical instruments (notably thrombectomy and vascular devices) that just crossed a major profitability inflection. FY2025 revenue grew 17.5% to $1.40B, but the operating leverage is the story: gross margin reached 67.1%, operating income surged to $189M (from a near-breakeven prior year) and net income jumped to $178M with diluted EPS of $4.52. Operating cash flow rose 41.7% to $239M, and the balance sheet is pristine — liabilities/equity of just 0.28x, equity up 24.0% to $1.43B and effectively no debt burden.
Sources: SEC EDGAR (CIK 0001321732, latest 10-Q filed 2026-05-06) · analysis by claude-code · as of 6/21/2026, 8:46:03 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $748M | $847M | $1.06B | $1.19B | $1.40B |
| Gross profit | $475M | $535M | $683M | $755M | $942M |
| Operating income | -$7.50M | $6.08M | $73.6M | $9.28M | $189M |
| Net income | $5.28M | -$2.00M | $91.0M | $14.0M | $178M |
| Diluted EPS | $0.14 | -$0.05 | $2.32 | $0.36 | $4.52 |
| Net margin | 0.7% | -0.2% | 8.6% | 1.2% | 12.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1046 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 1 sale
| 2026-05-19 | Elsesser Adam CEO | Gift | 77.0K | |
| 2026-04-02 | Grewal Harpreet Director | Sell | 100.00 @ $328.22 | $32.8K |
| 2026-03-15 | Narayan Shruthi President | Tax | 117.00 @ $336.18 | $39.3K |
| 2026-03-15 | Roberts Johanna EVP, Gen. Counsel & Secretary | Tax | 186.00 @ $336.18 | $62.5K |
| 2026-03-15 | Yuen Maggie Chief Financial Officer | Tax | 186.00 @ $336.18 | $62.5K |
| 2026-03-15 | Shiu Lambert Chief Accounting Officer | Tax | 150.00 @ $336.18 | $50.4K |
| 2026-03-02 | Yuen Maggie Chief Financial Officer | Sell | 2.43K @ $342.30 | $832K |
| 2026-02-13 | Grewal Harpreet Director | Award | 589.00 |